Richard LeBlanc
- Hematology top 0.2%
- Multiple Myeloma Research and Treatments 87
- Hematopoietic Stem Cell Transplantation 7
- Oncology top 2%
- Cancer Treatment and Pharmacology 27
- Peptidase Inhibition and Analysis 22
- Molecular Biology top 5%
- Protein Degradation and Inhibitors 37
- Cancer therapeutics and mechanisms 12
- Ubiquitin and proteasome pathways 7
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 8
- Immunology top 10%
- Co-authors
- Kenneth C. AndersonTeru HideshimaPaul G. RichardsonLaurence CatleyDharminder ChauhanNikhil C. MunshiNicholas MitsiadesConstantine S. Mitsiades
- Cited by
- HematologyOncologyMolecular Biology
- Journals
- New England Journal of Medicine (1 paper)Journal of Clinical Oncology (9 papers)SHILAP Revista de lepidopterología (2 papers)
- Partner nations
- CanadaUnited StatesFrance
In The Last Decade
Richard LeBlanc
99 papers receiving 3.1k citations
Hit Papers
Peers
Comparison fields: 5 of 101
- Hematology 2.2k
- Oncology 1.5k
- Molecular Biology 2.2k
- Genetics 308
- Immunology 302
Countries citing papers authored by Richard LeBlanc
This map shows the geographic impact of Richard LeBlanc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard LeBlanc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard LeBlanc more than expected).
Fields of papers citing papers by Richard LeBlanc
This network shows the impact of papers produced by Richard LeBlanc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard LeBlanc. The network helps show where Richard LeBlanc may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Richard LeBlanc, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 1 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 1 | |
| 7 | 2022 | 0 | |
| 8 | 2022 | 2 | |
| 9 | 2017 | 4 | |
| 10 | 2017 | 0 | |
| 11 | 2017 | 2 | |
| 12 | 2017 | 3 | |
| 13 | Canadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous stem cell transplant. | 2016 | 7 |
| 14 | 2006 | 9 | |
| 15 | Thalidomide analogue IMiD3 provides T cell co-stimulation through B7-CD28 pathway. | 2002 | 1 |
| 16 | LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma: Results of a pre-clinical evaluation in vitro and in vivo. | 2002 | 5 |
| 17 | Heat shock protein-27 confers drug-resistance in multiple myeloma cells. | 2002 | 2 |
| 18 | 2-methoxyestradiol (2ME2) acts directly on tumor cells and in the bone marrow microenvironment to overcome drug resistance in multiple myeloma (MM) cells. | 2001 | 3 |
| 19 | Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model. | 2001 | 11 |
| 20 | 1998 | 15 |
About Richard LeBlanc
Richard LeBlanc is a scholar working on Hematology, Oncology and Genetics, having authored 107 papers that have together received 3.2k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (87 papers), Protein Degradation and Inhibitors (37 papers), Cancer Treatment and Pharmacology (27 papers), Peptidase Inhibition and Analysis (22 papers), Cancer therapeutics and mechanisms (12 papers), Chronic Lymphocytic Leukemia Research (8 papers), Ubiquitin and proteasome pathways (7 papers) and Hematopoietic Stem Cell Transplantation (7 papers). The work is most often cited by research in Hematology (2.2k citations), Oncology (1.5k citations) and Molecular Biology (2.2k citations). Richard LeBlanc has collaborated with scholars based in Canada, United States and France. Frequent co-authors include Kenneth C. Anderson, Teru Hideshima, Paul G. Richardson, Laurence Catley, Dharminder Chauhan, Nikhil C. Munshi, Nicholas Mitsiades, Constantine S. Mitsiades, Suzanne Lentzsch and Robert Schlossman. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.